S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
OTCMKTS:INNV

InnovAge - INNV Competitors

$6.08
-0.39 (-6.03%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.77
$6.47
50-Day Range
$5.77
$7.72
52-Week Range
$3.39
$8.03
Volume
26,988 shs
Average Volume
30,296 shs
Market Capitalization
$824.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.48

INNV vs. DCGO, SHCR, USPH, PNTG, CRHM, LFST, PRVA, GERN, QURE, and BHVN

Should you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include DocGo (DCGO), Sharecare (SHCR), U.S. Physical Therapy (USPH), The Pennant Group (PNTG), CRH Medical (CRHM), LifeStance Health Group (LFST), Privia Health Group (PRVA), Geron (GERN), uniQure (QURE), and Biohaven (BHVN). These companies are all part of the "medical" sector.

InnovAge vs.

InnovAge (OTCMKTS:INNV) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability.

DocGo has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovAge$698.64 million1.18-$6.52 million-$0.28-21.71
DocGo$440.52 million2.03$34.58 million$0.3227.28

InnovAge currently has a consensus target price of $6.48, suggesting a potential upside of 6.63%. DocGo has a consensus target price of $11.67, suggesting a potential upside of 33.64%. Given DocGo's stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than InnovAge.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InnovAge
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
DocGo
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

DocGo has a net margin of 7.85% compared to InnovAge's net margin of -5.57%. DocGo's return on equity of 12.80% beat InnovAge's return on equity.

Company Net Margins Return on Equity Return on Assets
InnovAge -5.57% -11.52% -6.84%
DocGo 7.85% 12.80% 9.50%

In the previous week, DocGo had 2 more articles in the media than InnovAge. MarketBeat recorded 2 mentions for DocGo and 0 mentions for InnovAge. DocGo's average media sentiment score of 0.27 beat InnovAge's score of 0.09 indicating that DocGo is being referred to more favorably in the news media.

Company Overall Sentiment
InnovAge Neutral
DocGo Neutral

InnovAge received 118 more outperform votes than DocGo when rated by MarketBeat users. Likewise, 60.00% of users gave InnovAge an outperform vote while only 58.62% of users gave DocGo an outperform vote.

CompanyUnderperformOutperform
InnovAgeOutperform Votes
135
60.00%
Underperform Votes
90
40.00%
DocGoOutperform Votes
17
58.62%
Underperform Votes
12
41.38%

12.4% of InnovAge shares are owned by institutional investors. Comparatively, 36.9% of DocGo shares are owned by institutional investors. 0.3% of InnovAge shares are owned by insiders. Comparatively, 19.7% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

InnovAge has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500. Comparatively, DocGo has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Summary

DocGo beats InnovAge on 15 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INNV vs. The Competition

MetricInnovAgeHealth services IndustryMedical SectorOTCMKTS Exchange
Market Cap$881.38M$1.07B$4.36B$7.74B
Dividend YieldN/A1.80%2.39%18.16%
P/E Ratio-21.7112.03103.518.89
Price / Sales1.18116.273,536.26282.61
Price / Cash73.6920.1527.0519.85
Price / Book2.431.884.466.76
Net Income-$6.52M-$93.36M$115.14M$743.32M
7 Day Performance2.01%-1.53%-1.06%0.91%
1 Month Performance-18.93%-16.48%-6.88%-1.14%
1 Year Performance4.65%9.83%-16.84%-9.63%

InnovAge Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DCGO
DocGo
2.2214 of 5 stars
$8.41
-0.7%
$11.67
+38.7%
+2.6%$861.27M$440.52M26.283,252
SHCR
Sharecare
1.9335 of 5 stars
$2.13
-7.0%
$3.12
+46.5%
-34.8%$753.00M$412.82M-8.523,279Upcoming Earnings
USPH
U.S. Physical Therapy
2.3661 of 5 stars
$93.19
-2.6%
$110.00
+18.0%
-3.4%$1.21B$553.14M41.426,135
PNTG
The Pennant Group
3.0566 of 5 stars
$12.09
-1.3%
$17.00
+40.6%
-23.9%$359.19M$473.24M54.965,335Positive News
CRHM
CRH Medical
0 of 5 stars
$3.99
flat
N/AN/A$285.76M$120.39M-66.50133
LFST
LifeStance Health Group
1.6386 of 5 stars
$7.00
+4.8%
$7.85
+12.1%
-24.7%$2.63B$859.54M-11.487,830High Trading Volume
PRVA
Privia Health Group
2.6361 of 5 stars
$26.35
-2.6%
$38.73
+47.0%
+8.8%$3.03B$1.36B-239.55810Insider Selling
GERN
Geron
1.9386 of 5 stars
$2.30
-1.7%
$5.50
+139.1%
+90.0%$876.83M$600,000.00-6.3969
QURE
uniQure
1.5348 of 5 stars
$18.70
-3.9%
$55.13
+194.8%
+19.0%$878.53M$106.48M-6.90463
BHVN
Biohaven
1.9763 of 5 stars
$12.94
-5.9%
$48.75
+276.7%
-88.2%$881.99M$462.51M-0.93928
This page (OTCMKTS:INNV) was last updated on 3/24/2023 by MarketBeat.com Staff